Moleculin Biotech CS (MBRX)

$0.87 -0.04 (-4.80%)
Market Cap 12.25M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 272,700
Avg Vol 7,010,842
Day's Range N/A - N/A
Shares Out 14.00M
Stochastic %K 51%
Beta 2.19
Analysts Strong Sell
Price Target $10.67

Latest News on MBRX

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 3 days ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 19 days ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 27 days ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 27 days ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 4 weeks ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 5 weeks ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 5 weeks ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 6, 2025, 8:30 AM EST - 6 weeks ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Mar 3, 2025, 8:30 AM EST - 6 weeks ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 25, 2025, 12:35 PM EST - 7 weeks ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:19 PM EST - 2 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 1:05 PM EST - 2 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 13, 2025, 9:25 AM EST - 2 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Feb 11, 2025, 8:40 AM EST - 2 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 27, 2025, 8:30 AM EST - 2 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Jan 8, 2025, 8:30 AM EST - 3 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Dec 11, 2024, 8:00 AM EST - 4 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 18, 2024, 8:15 AM EST - 5 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 14, 2024, 8:15 AM EST - 5 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 12, 2024, 8:00 AM EST - 5 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:17 AM EST - 5 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 7:05 AM EST - 5 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 5, 2024, 9:00 AM EST - 5 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Nov 4, 2024, 8:30 AM EST - 5 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 17, 2024, 8:40 AM EDT - 6 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Oct 7, 2024, 8:30 AM EDT - 6 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Moleculin to Present at Two Upcoming Investor Conferences

Oct 4, 2024, 9:00 AM EDT - 7 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Sep 23, 2024, 8:00 AM EDT - 7 months ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

Moleculin Participates in Virtual Investor "What this Means" Segment

Sep 16, 2024, 8:30 AM EDT - 7 months ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Sep 9, 2024, 8:15 AM EDT - 7 months ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 9:15 AM EDT - 8 months ago

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Aug 26, 2024, 8:30 AM EDT - 8 months ago

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Moleculin Announces Closing of up to $16.5 Million Public Offering

Aug 19, 2024, 4:05 PM EDT - 8 months ago

Moleculin Announces Closing of up to $16.5 Million Public Offering

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 8 months ago

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

Aug 5, 2024, 9:05 AM EDT - 9 months ago

Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

Aug 1, 2024, 8:30 AM EDT - 9 months ago

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Jul 10, 2024, 8:30 AM EDT - 10 months ago

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Jun 14, 2024, 8:00 AM EDT - 11 months ago

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin to Present at the Virtual Investor Pitch Conference

Jun 12, 2024, 9:00 AM EDT - 11 months ago

Moleculin to Present at the Virtual Investor Pitch Conference

Moleculin to Participate in the Virtual Investor Lunch Break Series

Jun 5, 2024, 8:55 AM EDT - 11 months ago

Moleculin to Participate in the Virtual Investor Lunch Break Series

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

May 16, 2024, 8:32 AM EDT - 1 year ago

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

May 15, 2024, 8:38 AM EDT - 1 year ago

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript

May 13, 2024, 11:44 AM EDT - 1 year ago

Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 7:30 AM EDT - 1 year ago

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

May 9, 2024, 8:30 AM EDT - 1 year ago

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

May 8, 2024, 8:45 AM EDT - 1 year ago

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

May 7, 2024, 8:55 AM EDT - 1 year ago

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

May 1, 2024, 8:50 AM EDT - 1 year ago

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Apr 25, 2024, 9:45 AM EDT - 1 year ago

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team